A Randomized Controlled Study of Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- the level of anxiety
Study Overview
Brief Summary
To explore the efficacy of drugs combined with virtual reality exposure therapy in the treatment of phobias compared with single drug treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Meet the diagnostic criteria for phobias in DSM-IV.
- •Age from 18 to 45 years old.
- •Graduated from junior high school or above.
- •No serious physical disease, no serious visual impairment, and no family history of mental illness.
Exclusion Criteria
- •Exclude other psychiatric diagnosis and treatment history.
Arms & Interventions
drug only
Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
Intervention: Sertraline (Drug)
vert combine with drug
On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
Intervention: vert (Device)
vert combine with drug
On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
Intervention: Sertraline (Drug)
Outcomes
Primary Outcomes
the level of anxiety
Time Frame: 3 months
the score of Hamilton anxiety scale, the minimum and maximum values are 0 and 56, and higher scores mean a worse outcome.
heart rate of the patients
Time Frame: 3 months
take the heart rate as a biomarker of fear, the faster heart rate means the participate is more afraid
Secondary Outcomes
No secondary outcomes reported